A potent inhibitor poly(ADP-ribose) polymerase (PARP; IC₅₀ = 0.40 µM). Has been shown to potentiate the cytotoxicity of the DNA-methylating agent MTIC [5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide] and ionizing irradiation in murine L210 leukemia cells.

A potent poly(ADP-ribose) polymerase (PARP) inhibitor (IC₅₀ = 400 nM) that potentiates the cytotoxicity of various DNA-active agents, including the DNA-methylating compound MTIC [5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide], the DNA strand break-inducing drug temozolomide, topotecan, bleomycin, and ionizing radiation in murine L1210 leukemia cells, Chinese hamster ovary cells, and in a variety of human tumor cell lines.

Cell permeable: no

Primary Target
PARP

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 0.4 µM against poly(ADP-ribose) polymerase (PARP)

Packaged under inert gas

Toxicity: Standard Handling (A)

This solution can be further diluted 1:100 in tissue culture medium before use.

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Delaney, C.A., et al. 2000. Clin. Cancer Res.6, 2860.
Boulton, S., et al. 1999. Carcinogenesis20, 199.
Bowman, K.J., et al. 1998. Br. J. Cancer 78, 1269.
Griffin, R.J., et al. 1998. J. Med. Chem. 41, 5247.
Griffin, R.J., et al. 1996. Pharm. Sci. 2, 43.
Boulton, S., et al. 1995. Br. J. Cancer 72, 849.
Griffin, R.J., et al. 1995. Anticancer Drug Res. 10, 507.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany